Alto Neuroscience is leveraging Trump-era tariffs and AI trends to advance its drug candidate ALTO-203 for Major Depressive Disorder (MDD).
2 reports, 2 independent
Updated Aug 20
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alto Neuroscience is leveraging Trump-era tariffs and AI trends to advance its drug candidate ALTO-203 for Major Depressive Disorder (MDD).
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Amit Etkin was appointed Founder and CEO of Alto Neuroscience on August 14, 2025.Sub-event
Alto Neuroscience is advancing drug candidate ALTO-203 for MDD, benefiting from Trump-era tariffs and AI trends.1 source
Keep exploring
The entities involved
-
Alto Neuroscience (United States)
company in Los Altos, United States
Nothing else this week.
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
Coverage
Newest first; wire copies grouped- Insider MonkeyAlto Neuroscience’s Depression Drug Shows Positive Biomarker Results in Phase 2 Trial Alto Neuroscience Inc. (NYSE:ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On Jun
- Business WireAlto Neuroscience to Participate in Upcoming Investor Conferences MOUNTAIN VIEW, Calif., August 18, 2025--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceut